Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Alkermes plc Reports Second Quarter 2022 Financial Results

      This image opens in the lightbox

      News provided by

      Alkermes plc

      27 Jul, 2022, 11:00 GMT

      Share this article

      Share this article


      —    Second Quarter Revenues of $276.2 Million Reflect Strong Growth in Proprietary Net Sales —

      —    GAAP Loss per Share of $0.18 and Non-GAAP Earnings per Share of $0.06 —

      —    Raises Financial Expectations for Full-Year 2022—

      DUBLIN, July 27, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2022 and provided updated financial expectations for full-year 2022.

      "In the second quarter, Alkermes continued to execute successfully across the business. VIVITROL® and ARISTADA® both grew year-over-year and sequentially, and LYBALVI® continued on a strong launch trajectory," commented Iain Brown, Chief Financial Officer of Alkermes. "Today, we are pleased to be raising our financial expectations for full-year 2022, primarily due to LYBALVI's launch performance and updated assumptions related to continued royalty revenues on sales of long-acting INVEGA® products outside of the U.S. We believe that we are well positioned to continue to make meaningful progress against our strategic priorities and to drive shareholder value."

      Quarter Ended June 30, 2022 Financial Results

      Revenues

      - Total revenues for the quarter were $276.2 million, compared to $303.7 million for the same period in the prior year.

      - Net sales of proprietary products for the quarter were $190.8 million, compared to $160.8 million for the same period in the prior year.

      • Net sales of VIVITROL were $96.1 million, compared to $88.4 million for the same period in the prior year, representing an increase of approximately 9%.
      • Net sales of ARISTADAi were $74.6 million, compared to $72.4 million for the same period in the prior year, representing an increase of approximately 3%.
      • Net sales of LYBALVI were $20.1 million, following its commercial launch in October 2021.

      - Manufacturing and royalty revenues for the quarter were $85.3 million, compared to $142.3 million for the same period in the prior year.

      • Royalty revenues from INVEGA SUSTENNA®/XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® (the long-acting INVEGA products) were $26.6 million, compared to $81.1 million for the same period in the prior year. This decrease was driven primarily by Janssen Pharmaceutica N.V.'s (Janssen) partial termination of the license agreement related to sales of the long-acting INVEGA products in the United States (U.S.).
      • Manufacturing and royalty revenues from VUMERITY® were $26.2 million, compared to $20.3 million for the same period in the prior year.

      Costs and Expenses

      - Total operating expenses for the quarter were $310.7 million, compared to $299.3 million for the same period in the prior year, primarily reflecting increased investment to support the commercial launch of LYBALVI.

      • Cost of Goods Manufactured and Sold were $58.4 million, compared to $53.1 million for the same period in the prior year.
      • Research and Development (R&D) expenses were $92.9 million, compared to $97.5 million for the same period in the prior year.
      • Selling, General and Administrative (SG&A) expenses were $150.4 million, compared to $139.2 million for the same period in the prior year.

      Profitability

      - Net loss according to generally accepted accounting principles in the U.S. (GAAP) was $30.1 million for the quarter, or a basic and diluted GAAP loss per share of $0.18. This compared to GAAP net income of $2.4 million, or a basic and diluted GAAP earnings per share of $0.01, for the same period in the prior year.

      - Non-GAAP net income was $10.5 million for the quarter, or a non-GAAP basic and diluted earnings per share of $0.06. This compared to non-GAAP net income of $49.2 million for the quarter, or a non-GAAP basic earnings per share of $0.31 and a diluted earnings per share of $0.30, for the same period in the prior year.

      Balance Sheet

      - At June 30, 2022, the company recorded cash, cash equivalents and total investments of $760.0 million, compared to $758.7 million at March 31, 2022. The company's total debt outstanding as of June 30, 2022 was $294.5 million.

      "Our second quarter results reflect revenue growth from our proprietary commercial portfolio, highlighted by our continued progress in the launch of LYBALVI, a new oral treatment for schizophrenia and bipolar I disorder," said Richard Pops, Chief Executive Officer of Alkermes. "At the same time, we continued to make progress in our development pipeline, highlighted by the presentation of nemvaleukin ARTISTRY-1 data at the 2022 ASCO annual meeting. As we strive to make a meaningful impact on the lives of patients and families, we will continue to focus on execution against our strategic priorities and our commitment to deliver value for our shareholders."

      Financial Expectations for 2022

      The following updated financial expectations for 2022 primarily reflect LYBALVI's launch performance to date and the company's current assumption that it will continue to receive royalty payments related to sales of the long-acting INVEGA products outside the U.S. through at least October 2022. All line items are according to GAAP, except as otherwise noted.

      In millions (except per share amounts)


      Current 2022
      Expectation

      (Provided 7/27/22)

      Prior 2022

      Expectation

      (Provided 2/16/22)





      Total Revenue


      $1,050 – $1,120

      $1,000 – $1,090

      VIVITROL Net Sales


      $365 – $385

      $355 – $385

      ARISTADA Net Sales


      $295 – $315

      $290 – $320

      LYBALVI Net Sales


      $75 – $90

      $55 – $75

           INVEGA Franchise Royalties*


      $95 – $100

      $45 – $50

      Other revenues


      $220 – $230

      $255 - $260

      Cost of Goods Sold


      $215 – $225

      $215 – $225

      R&D Expenses


      $380 – $400

      $385 – $415

      SG&A Expenses


      $575 – $605

      $575 – $605

      Amortization of Intangible Assets


      ~$35

      ~$35

      Interest Expense, Net


      $5 – $10

      $5 – $10

      Other Expense, Net


      ~$15

      $0

      Income Tax Benefit


      $10 – $15

      $10 – $15

      GAAP Net Loss


      ($145) – ($175)

      ($180) – ($210)

      GAAP Net Loss per Share+


      ($0.88) – ($1.07)

      ($1.10) – ($1.29)

      Non-GAAP Net Income (Loss)


      $15 – $45

      ($30) – $0

      Non-GAAP Earnings (Loss) Per Share+


      $0.09 – $0.27

      ($0.18) – $0.00

      Capital Expenditures


      $35 – $40

      $35 – $40

      *Reflects royalties related to sales of INVEGA SUSTENNA/INVEGA TRINZA/INVEGA HAFYERA in the U.S. through January 2022 and royalties related to sales of XEPLION/TREVICTA/BYANNLI through October 2022.

      + Current 2022 per share expectations are calculated based on a weighted average basic share count of approximately 164.0 million shares outstanding and a weighted average diluted share count of approximately 169.0 million shares outstanding.

      Recent Events:

      Oncology

      • In June 2022, the company presented data from its phase 1/2 ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Annual Meeting. Trial-in-progress posters from the ongoing ARTISTRY-3 trial and the potential registration-enabling ARTISTRY-6 and ARTISTRY-7 trials were also presented at the ASCO meeting.

      Psychiatry

      • In May 2022, the company presented research related to its psychiatry portfolio at four scientific conferences. The meetings included: American Telemedicine Association (ATA) Annual Conference, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, American Psychiatric Association (APA) Annual Meeting, and American Society of Clinical Psychopharmacology (ASCP) Annual Conference.

      Other

      • In May 2022, the company announced a series of actions as part of its ongoing commitment to strong corporate governance and regular board refreshment, including the appointment to the company's Board of Directors (the Board) of Christopher I. Wright, M.D., Ph.D., a new, independent director with neuroscience and drug development expertise and the seventh independent director to join the Board in the last three years; the appointment of Nancy J. Wysenski as Lead Independent Director of the Board; and the retirement from the Board of two longer-serving directors, David W. Anstice AO and Wendy L. Dixon, Ph.D.

      Conference Call

      Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 27, 2022, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call will be available from 11:00 a.m. ET (4:00 p.m. BST) on Wednesday, July 27, 2022, through Wednesday, August 3, 2022, and may be accessed by visiting Alkermes' website or by dialing +1 877 660 6853 for U.S. callers and +1 201 612 7415 for international callers. The replay conference ID is 13731319.

      About Alkermes plc

      Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

      Non-GAAP Financial Measures

      This press release includes information about certain financial measures that are not prepared in accordance with GAAP, including non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

      Non-GAAP net income (loss) adjusts for certain one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; change in the fair value of contingent consideration; certain other one-time or non-cash items; and the income tax effect of these reconciling items.

      The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP financial measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share should not be considered measures of the company's liquidity.

      A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

      Note Regarding Forward-Looking Statements

      Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning its future financial and operating performance, business plans or prospects, including its assumptions regarding royalty payments on sales of the long-acting INVEGA products outside the U.S., its commitment and plans to drive shareholder value, and its ability to execute on its strategic priorities; and the potential therapeutic and commercial value of the company's products. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the company's efforts to manage its cost structure may not yield the intended results; the company may not be able to achieve long-term profitability or its profitability targets in a timely manner or at all; the impacts of the ongoing COVID-19 pandemic on the company's business, results of operations or financial condition, including impacts on healthcare systems and on patient and healthcare provider access to the company's marketed products; the unfavorable outcome of arbitration or litigation, including so-called "Paragraph IV" litigation and other patent litigation, or other disputes related to the company's products or products using the company's proprietary technologies, including the arbitration proceedings with Janssen; clinical development activities may not be completed on time or at all; the results of the company's development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; the U.S. Food and Drug Administration (FDA) may not agree with the company's regulatory approval strategies or components of the company's marketing applications; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to government payers; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended Dec. 31, 2021 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

      VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA®, ARISTADA INITIO® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; BYANNLI®, INVEGA®, INVEGA HAFYERA®, INVEGA SUSTENNA®, INVEGA TRINZA®, TREVICTA® and XEPLION® are registered trademarks of Johnson & Johnson Corporation; and VUMERITY® is a registered trademark of Biogen Inc., used by Alkermes under license.

      (tables follow)





      i The term "ARISTADA" as used in this press release refers to ARISTADA and ARISTADA INITIO®, unless the context indicates otherwise.

      Alkermes plc and Subsidiaries


      Selected Financial Information (Unaudited)








      Condensed Consolidated Statements of Operations - GAAP


      Three Months Ended 


      Three Months Ended 


      (In thousands, except per share data)


      June 30, 2022


      June 30, 2021


      Revenues:






      Product sales, net


      $                  190,787


      $                  160,808


      Manufacturing and royalty revenues


      85,326


      142,294


      Research and development revenue


      106


      615


      Total Revenues


      276,219


      303,717


      Expenses:






      Cost of goods manufactured and sold


      58,360


      53,124


      Research and development


      92,873


      97,473


      Selling, general and administrative


      150,377


      139,188


      Amortization of acquired intangible assets


      9,066


      9,511


      Total Expenses


      310,676


      299,296


      Operating (Loss) Income


      (34,457)


      4,421


      Other Income, net:






      Interest income


      896


      623


      Interest expense


      (2,369)


      (2,407)


      Change in the fair value of contingent consideration


      870


      3,240


      Other income (expense), net


      1,810


      (222)


      Total Other Income, net


      1,207


      1,234


      (Loss) Income Before Income Taxes


      (33,250)


      5,655


      (Benefit) Provision for Income Taxes


      (3,114)


      3,291


      Net (Loss) Income — GAAP


      $                  (30,136)


      $                      2,364








      (Loss) Earnings Per Share:






      GAAP (loss) earnings per share — basic and diluted


      $                      (0.18)


      $                        0.01


      Non-GAAP earnings per share — basic


      $                        0.06


      $                        0.31


      Non-GAAP earnings per share — diluted


      $                        0.06


      $                        0.30








      Weighted Average Number of Ordinary Shares Outstanding:






      Basic — GAAP


      163,839


      160,817


      Diluted — GAAP 


      163,839


      163,937


      Basic — Non-GAAP


      163,839


      160,817


      Diluted — Non-GAAP


      168,706


      163,937








      An itemized reconciliation between net (loss) income on a GAAP basis and non-GAAP net income is as follows:


      Net (Loss) Income — GAAP


      $                  (30,136)


      $                      2,364


      Adjustments:






      Share-based compensation expense


      23,377


      27,552


      Depreciation expense


      10,326


      8,966


      Amortization expense


      9,066


      9,511


      Income tax effect related to reconciling items


      (1,383)


      3,927


      Non-cash net interest expense


      117


      117


      Change in the fair value of contingent consideration


      (870)


      (3,240)


      Non-GAAP Net Income


      $                    10,497


      $                    49,197




















      Condensed Consolidated Statements of Operations - GAAP


      Six Months Ended 


      Six Months Ended 


      (In thousands, except per share data)


      June 30, 2022


      June 30, 2021


      Revenues:






      Product sales, net


      $                  362,055


      $                  290,771


      Manufacturing and royalty revenues


      190,496


      262,141


      License revenue


      2,000


      1,500


      Research and development revenue


      213


      735


      Total Revenues


      554,764


      555,147


      Expenses:






      Cost of goods manufactured and sold


      113,519


      94,144


      Research and development


      188,826


      189,741


      Selling, general and administrative


      295,429


      264,356


      Amortization of acquired intangible assets


      18,032


      18,917


      Total Expenses


      615,806


      567,158


      Operating Loss


      (61,042)


      (12,011)


      Other Expense, net:






        Interest income


      1,469


      1,487


        Interest expense


      (4,719)


      (6,377)


        Change in the fair value of contingent consideration


      (18,197)


      4,518


        Other income (expense), net


      4,241


      (615)


      Total Other Expense, net


      (17,206)


      (987)


      Loss Before Income Taxes


      (78,248)


      (12,998)


      (Benefit) Provision for Income Taxes


      (12,209)


      7,056


      Net Loss — GAAP


      $                  (66,039)


      $                  (20,054)








      (Loss) Earnings Per Share:






      GAAP loss per share — basic and diluted


      $                      (0.40)


      $                      (0.13)


      Non-GAAP earnings per share — basic


      $                        0.18


      $                        0.42


      Non-GAAP earnings per share — diluted


      $                        0.18


      $                        0.41








      Weighted Average Number of Ordinary Shares Outstanding:






      Basic and diluted — GAAP


      163,165


      160,229


      Basic — Non-GAAP


      163,165


      160,229


      Diluted — Non-GAAP


      167,372


      163,174








      An itemized reconciliation between net loss on a GAAP basis and non-GAAP net income is as follows:


      Net Loss — GAAP


      $                  (66,039)


      $                  (20,054)


      Adjustments:






      Share-based compensation expense


      41,720


      43,003


      Depreciation expense


      20,557


      19,203


      Amortization expense


      18,032


      18,917


      Income tax effect related to reconciling items


      (2,576)


      8,106


      Non-cash net interest expense


      234


      235


      Change in the fair value of contingent consideration


      18,197


      (4,518)


      Debt refinancing charge


      —


      2,109


      Non-GAAP Net Income


      $                    30,125


      $                    67,001














      Condensed Consolidated Balance Sheets


      June 30, 


      December 31, 


      (In thousands)


      2022


      2021


      Cash, cash equivalents and total investments


      $                  759,977


      $                  765,741


      Receivables


      245,840


      313,193


      Inventory


      155,608


      150,335


      Contract assets


      16,486


      13,363


      Prepaid expenses and other current assets


      47,090


      48,967


      Property, plant and equipment, net


      337,146


      341,054


      Intangible assets, net and goodwill


      148,884


      166,916


      Other assets


      246,386


      224,915


      Total Assets


      $               1,957,417


      $               2,024,484


      Long-term debt — current portion


      $                      3,000


      $                      3,000


      Other current liabilities


      435,518


      468,286


      Long-term debt   


      291,537


      292,804


      Contract liabilities — long-term 






      Other long-term liabilities


      145,038


      147,810


      Total shareholders' equity


      1,082,324


      1,112,584


      Total Liabilities and Shareholders' Equity


      $               1,957,417


      $               2,024,484








      Ordinary shares outstanding (in thousands)


      164,233


      161,937








      This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in
      Alkermes plc's Quarterly Report on Form 10-Q for the three and six months ended June 30, 2022, which the company intends to file in July
      2022.














      2022 Guidance — GAAP to Non-GAAP Adjustments







      An itemized reconciliation between projected loss per share on a GAAP basis and projected earnings per share on a non-GAAP basis is as
      follows:







      (In millions, except per share data)


      Amount


      Shares


      Projected Net Loss — GAAP


      $                    (160.0)


      164


         Adjustments:






      Share-based compensation expense


      93.0




      Depreciation expense


      40.0




      Amortization expense


      35.0




      Change in the fair value of contingent consideration


      18.0




      Income tax effect related to reconciling items 


      3.0




      Other expense, net


      -




      Non-cash net interest expense


      1.0




      Projected Net Income — Non-GAAP


      $                        30.0


      169








      Projected GAAP and non-GAAP measures reflect mid-points within ranges of estimated guidance.

      Alkermes Contacts:
      For Investors: Sandy Coombs   +1 781 609 6377
      For Media:      Katie Joyce        +1 781 249 8927

      Logo - https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.